SEARCH

SEARCH BY CITATION

References

  • 1
    Colonna L., Catalano G., Chew C., D’Agati V., Thomas J.W., Wong F.S., Schmitz J., Masuda E.S., Reizis B., Tarakhovsky A., Clynes R. (2010) Therapeutic targeting of Syk in autoimmune diabetes. J Immunol;185:15321543.
  • 2
    Efremov D.G., Laurenti L. (2011) The Syk kinase as a therapeutic target in leukemia and lymphoma. Expert Opin Investig Drugs;20:623636.
  • 3
    Gilfillan A.M., Rivera J. (2009) The tyrosine kinase network regulating mast cell activation. Immunol Rev;228:149169.
  • 4
    Pao L.I., Famiglietti S.J., Cambier J.C. (1998) Asymmetrical phosphorylation and function of immunoreceptor tyrosine-based activation motif tyrosines in B cell antigen receptor signal transduction. J Immunol;160:33053314.
  • 5
    Tsang E., Giannetti A.M., Shaw D., Dinh M., Tse J.K., Gandhi S. et al. (2008) Molecular mechanism of the Syk activation switch. J Biol Chem;283:3265032659.
  • 6
    Groesch T.D., Zhou F., Mattila S., Geahlen R.L., Post C.B. (2006) Structural basis for the requirement of two phosphotyrosine residues in signaling mediated by Syk tyrosine kinase. J Mol Biol;356:12221236.
  • 7
    Bradshaw J.M. (2010) The Src, Syk, and Tec family kinases: distinct types of molecular switches. Cell Signal;22:11751184.
  • 8
    Geahlen R.L. (2009) Syk and pTyr’d: signaling through the B cell antigen receptor. Biochim Biophys Acta;1793:11151127.
  • 9
    Frantz B., Klatt T., Pang M., Parsons J., Rolando A., Williams H. et al. (1998) The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry;37:1384613853.
  • 10
    Swinney D.C. (2004) Biochemical mechanisms of drug action: what does it take for s uccess? Nat Rev Drug Discov;3:801808.
  • 11
    Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science;289:19381942.
  • 12
    Wood E.R., Truesdale A.T., McDonald O.B., Yuan D., Hassell A., Dickerson S.H. et al. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib). Cancer Res;64:66526659.
  • 13
    Garuti L., Roberti M., Bottegoni G. (2010) Non-ATP competitive protein kinase inhibitors. Curr Med Chem;17:28042821.
  • 14
    Zuccotto F., Ardini E., Casale E., Angiolini M. (2010) Through the gatekeeper door: exploiting the active kinase conformation. J Med Chem;53:26812694.
  • 15
    Liu Y., Gray N.S. (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol;2:358364.
  • 16
    Okram B., Nagle A., Adrián F.J., Lee C., Ren P., Wang X. et al. (2006) A general strategy for creating “Inactive-Conformation” Abl inhibitors. Chem Biol;13:779786.
  • 17
    Huang W.-S., Zhu X., Wang Y., Azam M., Wen D., Sundaramoorthi R. et al. (2009) 9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation. J Med Chem;52:47434756.
  • 18
    Klüter S., Grütter C., Naqvi T., Rabiller M., Simard J.R., Pawar V. et al. (2009) Displacement assay for the detection of stabilizers of inactive kinase conformations. J Med Chem;53:357367.
  • 19
    Tecle H., Feru F., Liu H., Kuhn C., Rennie G., Morris M., Shao J. (2009) The design, synthesis and potential utility of fluorescence probes that target DFG-out conformation of p38 for high throughput screening binding assay. Chem Biol Drug Des;74:547559.
  • 20
    Munoz L., Selig R., Yeung Y.T., Peifer C., Hauser D., Laufer S. (2010) Fluorescence polarization binding assay to develop inhibitors of inactive p38a mitogen-activated protein kinase. Anal Biochem;401:125133.
  • 21
    Simard J.R., Klüter S., Grütter C., Getlik M., Rabiller M., Rode H.B. et al. (2009) A new screening assay for allosteric inhibitors of cSrc. Nat Chem Biol;5:394396.
  • 22
    Simard J.R., Getlik M., Grütter C., Pawar V., Wulfert S., Rabiller M. et al. (2009) Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors. J Am Chem Soc;131:1328613296.
  • 23
    Simard J.R., Grütter C., Pawar V., Aust B., Wolf A., Rabiller M. et al. (2009) High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38a. J Am Chem Soc;131:1847818488.
  • 24
    Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D.R., Miller W.T. et al. (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res;62:42364243.
  • 25
    Atwell S., Adams J.M., Badger J., Buchanan M.D., Feil I.K., Froning K.J. et al. (2004) A novel mode of gleevec binding is revealed by the structure of spleen tyrosine kinase. J Biol Chem;279:5582755832.
  • 26
    Brooijmans N., Mobilio D., Walker G., Nilakantan R., Denny R.A., Feyfant E. et al. (2010) A structural informatics approach to mine kinase knowledge bases. Drug Discovery Today;15:203209.
  • 27
    Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H. et al. (2000) The protein data bank. Nucleic Acids Research;28(1):235242.
  • 28
    Brooijmans N., Chang Y.-W., Mobilio D., Denny R.A., Humblet C. (2010) An enriched structural kinase database to enable kinome-wide structure-based analyses and drug discovery. Protein Sci;19:763774.
  • 29
    Williams D.H., Lamers M.B.A.C., Smith S., Cherry M. Crystal structure and binding pockets of human spleen tyrosine kinase catalytic domain and ligand complexes, and use for drug design and discovery. WO2004035604
  • 30
    Otwinowski Z., Minor W. (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol;276:307326.
  • 31
    McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. (2007) Phaser crystallographic software. J Appl Crystallogr;40:658674.
  • 32
    Murshudov G.N., Vagin A.A., Dodson E.J. (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr;53:240255.
  • 33
    Blanc E., Roversi P., Vonrhein C., Flensburg C., Lea S.M., Bricogne G. (2004) Refinement of severely incomplete structures with maximum likelihood in BUSTER–TNT. Acta Crystallogr D Biol Crystallogr;60:22102221.
  • 34
    Emsley P., Cowtan K. (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr;60:21262132.
  • 35
    Higgs C., Sherman W. (2008) Probing flexibility in the activation loop of kinases. 17th European Symposium on QSAR in ”omics” and Systems Biology.
  • 36
    Backes A.C., Zech B., Felber B., Klebl B., Muller G. (2008) Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition. Expert Opin Drug Discov;3:14271449.
  • 37
    Kim K.S., Zhang L., Schmidt R., Cai Z.-W., Wei D., Williams D.K. et al. (2008) Discovery of pyrrolopyridinepyridone based inhibitors of met kinase: synthesis, X-ray crystallographic analysis, and biological activities. J Med Chem;51:53305341.
  • 38
    Harmange J.-C., Weiss M.M., Germain J., Polverino A.J., Borg G., Bready J. et al. (2008) Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation. J Med Chem;51:16491667.